Risks, benefits, and therapeutic potential of hematopoietic stem cell transplantation for autoimmune diabetes

Current Diabetes Reports

Volumn 12, Issue 5, 2012, Pages 604-611

  Couri, Carlos Eduardo Barra ^a   De Oliveira, Maria Carolina ^a   Simões, Belinda Pinto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autoimmune diabetes; Autologous transplantation; Cure; Diabetes; Hematopoietic; Immunosuppression; Stem cell; Type 1 diabetes

Indexed keywords

ABATACEPT; ACARBOSE; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DACLIZUMAB; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; RAPAMYCIN; SITAGLIPTIN; TEPLIZUMAB; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ENCEPHALOMYELITIS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; DIARRHEA; FEVER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; NAUSEA; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OLIGOSPERMIA; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PNEUMONIA; RASH; RISK BENEFIT ANALYSIS; STEM CELL MOBILIZATION; THERAPY EFFECT; URTICARIA; VOMITING;

AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84870833708     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0309-0     Document Type: Article

References (58)

1. Notkins AL, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest. 2001;108:1247-52 (Pubitemid 33107747)
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive insulin therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-9
3. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. Ann Intern Med. 1998;128:517-23
4. Couri CE, Foss MC, Voltarelli JC. Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting beta-cell regeneration. Braz J Med Biol Res. 2006;39:1271-80 (Pubitemid 46357869)
5. Lee S, Krause DS. Adult Stem Cell Plasticity. In: Burt RK, Marmont A, editors. Stem cell therapy for autoimmune disease, Chapter 11. Austin: Landes Biosciences; 2004. p. 59-76
6. Nagano K, Yoshida Y, Isobe T. Cell surface biomarkers of embryonic stem cells. Proteomics. 2008;8:4025-35
7. Witkowska-Zimny M, Wrobel E. Perinatal sources of mesenchymal stem cells: Wharton's Jelly, amnion and chorion. Cell Mol Biol Lett. 2011;16:493-514
8. Volarevic V, Ljujic B, Stojkovic P, Lukic A, Arsenijevic N, Stojkovic M. Human stem cell research and regenerative medicine-present and future. Br Med Bull. 2011;99:155-68
9. Hipp J, Atala A. Sources of stem cells for regenerative medicine. Stem Cell Rev. 2008;4:3-11
10. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells. 2009;27:2624-6
11. Gluckman E. Milestones in umbilical cord blood transplantation. Blood Rev. 2011;25:255-9
12. Carvalho MM, Teixeira FG, Reis RL, Sousa N, Salgado AJ. Mesenchymal stem cells in the umbilical cord: phenotypic characterization, secretome and applications in central nervous system regenerative medicine. Curr Stem Cell Res Ther. 2011;6:221-8
13. Pozzilli P, Di Mario U. Autoimune diabetes not requiring insulin at diagnosis (latent autoimune diabetes of the adult). Diabetes Care. 2001;24:1460-7
14. American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care. 2012;35:S4-10
15. Bennett ST, Todd JA. Human type 1A diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet. 1996;30:343-70 (Pubitemid 27014472)
16. Fairweather DL, Rose NR. Type 1 diabetes: virus infection or autoimmune disease? Nat Immunol. 2002;3:338-40 (Pubitemid 34308618)
17. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004;328:750-4 (Pubitemid 38406430)
18. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293-300
19. Eizirik DL, Mandrup-Poulsen T. A choice of death: the signal transduction of immune-mediated β-cell apoptosis. Diabetologia. 2001;44:2115-33 (Pubitemid 34015464)
20. Eizirik DL, Kutlu B, Rasschaert J, Darville M, Cardozo AK. Use of microarray analysis to unveil transcription factor and gene networks contributing to β-cell dysfunction and apoptosis. Am N Y Acad Sci. 2003;1005:55-74 (Pubitemid 38507734)
21. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54 (Suppl):S97-107
22. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA. 1992;89:2804-8
23. Morton JL, et al. Transplantation of autoimmune potential: development of antinuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand black mice. Proc Natl Acad Sci USA. 1974;71:2162-6
24. Van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant. 1996;18:1029-34 (Pubitemid 27026256)
25. Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med. 1993;178:1607-16 (Pubitemid 23318439)
26. Van Bekkum DW. New opportunities for the treatment of severe autoimmune diseases: bone marrow transplantation. Clin Immunol Immunopathol. 1998;89:1-10 (Pubitemid 28457880)
27. Knaan-Shanzer S, Houben P, Kinwel-Bohré EP, van Bekkum DW. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. Bone Marrow Transplant. 1991;8:333-8
28. Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol. 1997;24(Suppl):S23-9
29. Marmont AM. Coincidental autoimmune disease in patients transplanted for coincidental indications. Best Pract Res Clin Haematol. 2004;17:223-32 (Pubitemid 39145095)
30. Tamm M, Gratwohl A, Tichelli A, Perruchoud AP, Tyndall A. Autologous haematopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease. Ann Rheum Dis. 1996;55:779-80
31. Snowden JA, Brooks PM, Biggs JC. Haematopoietic stem cell transplantation for autoimmune disease. Br J Haematol. 1997;99:9-22 (Pubitemid 27461321)
32. Atkins HL, Muraro PA, van Laar JM, Pavletic SZ. Autologous hematopoietic stem cell transplantation for autoimmune disease-is it now ready for prime time? Biol Blood Marrow Transplant. 2012;18(Suppl):S177-83
33. McFarland RD, Douek DC, Koup RA, Picker LJ. Identification of a human recent thymic emigrant phenotype. Proc Natl Acad Sci USA. 2000;97:4215-20 (Pubitemid 30226113)
34. Burt RK, Verda L, Oyama Y, Statkute L, Slavin S. Non-myeloablative stem cell transplantation for autoimmune diseases. Springer Semin Immunopathol. 2004;26:57-69 (Pubitemid 40021957)
35. de Oliveira GL, Malmegrim KC, Ferreira AF, Tognon R, Kashima S, Couri CE, et al. Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation. Clin Exp Immunol. 2012;168:291-302
36. Kang EM, Zickler MM, Burns S, Langemeijer SM, Brenner S, Phang AO, et al. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol. 2005;33:699-705 (Pubitemid 40725836)
37. Yelin EH. The economic and functional impact of rheumatic disease in the US. In: Klippel JH, Dieppe PA. editors. Rheumatology. London: Mosby International. 1998. p. 1.5.1-1.5.4
38. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8:244-53
39. Couri CE, Voltarelli JC. Stem cell-based therapies and immunomodulatory approaches in newly diagnosed type 1 diabetes. Curr Stem Cell Res Ther. 2011;6:10-5
40. Fiorina P, Voltarelli J, Zavazava N. Immunological applications of stem cells in type 1 diabetes. Endocr Rev. 2011;32:725-54
41. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568-76 (Pubitemid 46588370)
42. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301:1573-9
43. Li L, Shen S, Ouyang J, Hu Y, Hu L, Cui W, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab. 2012;97:1729-36
44. Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Król M, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant. 2011;46:562-6
45. Snarski E, Torosian T, Paluszewska M, Urbanowska E, Milczarczyk A, Jedynasty K, et al. Alleviation of exogenous insulin requirement in type 1 diabetes mellitus after immunoablation and transplantation of autologous hematopoietic stem cells. Pol Arch Med Wewn. 2009;119:422-6
46. Sherry N, HagopianW, Ludvigsson J, Jain SM,Wahlen J, Ferry RJ Jr, et al. Teplizumab for treatment of type 1 diabetes (protégé study):1-year results from a randomized, placebo-controlled trial. Lancet. 2011;378:487-97
47. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new onset type 1 diabetes. Diabetes Care. 2010;33:826-32
48. Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, et al. Etanercept treatment in children with new-onset type 1 diabetes. Diabetes Care. 2009;32:1244-9
49. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomized, doubleblind, placebo-controlled trial. Lancet. 2011;378:412-9
50. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments tregs yet transiently impairs β-cell function. Diabetes. 2012. doi:10.2337/db12-0049
51. Liu J, Malhotra R, Voltarelli J. Ovarian recovery after stem cell transplantation. Bone Marrow Transplant. 2008;41:275-8 (Pubitemid 351260382)
52. Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996;87:3045-52
53. Tauchmanovà L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer. 2002;95:1076-84 (Pubitemid 34925360)
54. Tauchmanovà L, Selleri C, De Rosa G, Esposito M, Orio F Jr, Palomba S, et al. Gonadal status in reproductive age women after hematopoietic stem cell transplantation for hematological malignancies. Hum Reprod. 2003;18:1410-6 (Pubitemid 36840946)
55. Leal AM, Oliveira MC, Couri CE, Moraes DA, Stracieri AB, Pieroni F, et al. Testicular function in patients with type 1 diabetes treated with high-dose CY and autologous hematopoietic SCT. Bone Marrow Transplant. 2012;47:467-8
56. Au WY, Lie AK, Kung AW, Liang R, Hawkins BR, Kwong YL. Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:383-8 (Pubitemid 40309484)
57. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350:2068-79
58. ATrial of High Dose Immunosuppression and Autologous Hematopoietic Stem Cell Support Versus Intensive Insulin Therapy in Adults With Early Onset Type I Diabetes Mellitus. Available at: http://www.clinicaltrials.gov. Accessed 15 June 2012.